Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MEDI7183 low dose · 1 trial · 1 indication
Remission at Week 8 was defined as a total Mayo score 2 points or smaller, and with no individual subscore more than 1 point.
| Arm | Type | Description |
|---|---|---|
| MEDI7183 dose 1 | EXPERIMENTAL | Double blinded |
| MEDI7183 dose 2 | EXPERIMENTAL | Double blinded |
| MEDI7183 dose 3 | EXPERIMENTAL | Double blinded |
| Placebo | PLACEBO_COMPARATOR | Double blinded |
| Name | Type | Description |
|---|---|---|
| MEDI7183 low dose | DRUG | MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8 |
| MEDI7183 medium dose | DRUG | MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8 |
| MEDI7183 high dose | DRUG | MEDI7183 will be administered by SC on Day 1, and placebo for MEDI7183 at Week 2, 4, and 8 |
| Matching Placebo | DRUG | Placebo will be administered by SC on Day 1, Week 2,4, and 8 |
Inclusion Criteria: * Provision of informed consent prior to any study specific procedures * Diagnosis of UC established by clinical and endoscopic evidence and corroborated by a histopathology report * Moderate to severe active UC as defined by a total Mayo score of 6 to 12 with rectosigmoidoscopy...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Duvakitug |
| Eli Lilly and Company | LLY | 8 | PHASE3 | Mirikizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 10 | PHASE3 | Vedolizumab |
| Johnson & Johnson | JNJ | 13 | PHASE3 | Ustekinumab |
| AbbVie, Inc. | ABBV | 14 | PHASE3 | Upadacitinib |
| Merck & Co., Inc. | MRK | 3 | PHASE3 | Tulisokibart |
| Pfizer Inc. | PFE | 8 | PHASE3 | Etrasimod |
| Gilead Sciences, Inc. | GILD | 3 | PHASE3 | Filgotinib |
| Abivax SA Sponsored ADR | ABVX | 2 | PHASE3 | ABX464 |
| Bristol-Myers Squibb Company | BMY | 5 | PHASE2 | Ozanimod |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY001, SPY002, SPY003 |
| AnaptysBio, Inc. | ANAB | 1 | PHASE2 | Rosnilimab |
| Palatin Technologies, Inc. | PTN | 1 | PHASE2 | PL8177 |
| GSK plc Sponsored ADR | GSK | 1 | PHASE1 | GSK4528287 |
| Xencor, Inc. | XNCR | 1 | PHASE1 | XmAb942 |
| Sunshine Biopharma Incorporated | SBFM | 1 | PHASE2 | 627 |
| Amgen Inc. | AMGN | 1 | N/A | Undisclosed |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |
MEDI7183 low dose is an investigational small molecule being studied for the treatment of ulcerative colitis, a chronic inflammatory bowel disease. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
MEDI7183 low dose is being developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol AZN.
MEDI7183 low dose is in Phase 2 clinical development. It is an investigational drug and has not yet received regulatory approval for any indication.
MEDI7183 low dose has been studied in one completed Phase 2 clinical trial, identified as NCT01959165, which evaluated its safety and efficacy in Japanese patients with ulcerative colitis. The trial enrolled 44 participants.
MEDI7183 low dose is a specific dosage form of the investigational drug MEDI7183. The low dose designation refers to the particular dose level being evaluated in clinical studies for ulcerative colitis.